Deal talk and the first market read
Bloomberg reported Thursday that Sanofi is weighing a bid for Bridgewater, New Jersey-based Insmed Inc., whose market value sits near $32 billion. Both companies declined to comment.
Traders moved quickly. Insmed surged 21% on Thursday in New York. Sanofi fell 2.9% on Thursday, then edged higher by about 1.4% on Friday in Paris.
Why this target lines up with the plan
Garijo arrived to muted investor enthusiasm, but she has pushed through visible changes: scrapping certain pipeline drugs, selling legacy products, and tilting resources toward what she calls more innovative assets. She moved fast to broaden the Dupixent partnership with Regeneron, unveiling the update alongside Manuela Buxo, who now leads specialty care at Sanofi, a pairing that eased what had been a tense, litigation-heavy relationship.
Buying Insmed would track with her emphasis on commercial firepower and rare diseases while giving Sanofi time to repair a spotty internal R&D record. "Insmed would be a good fit for Sanofi," said Markus Manns of Union Investment, adding that the CEO's job is to use acquisitions to blunt the pending loss of exclusivity for Dupixent and to strengthen the pipeline. "Both of these goals would be achieved with Insmed." BMO's Conor MacKay echoed the logic, citing "an attractive combination of demonstrated commercial execution and additional pipeline opportunities."
What Sanofi would be buying - and the risks
Insmed has two respiratory drugs on the market: Brinsupri for bronchiectasis and Arikayce for a chronic lung disease. The company is also developing a therapy intended for serious illnesses such as idiopathic pulmonary fibrosis and interstitial lung disease. Analysts say that could fit with Sanofi's respiratory expertise if a deal happens, and former Sanofi CEO Paul Hudson was recently appointed to Insmed's board.
But expectations have been reset. Before the takeover chatter, Insmed shares were down about 30% this year as two studies failed to show Brinsupri benefited patients with other conditions. While the initial rollout was strong, Insmed's internal costs have kept rising, and some investors question whether early sales strength reflected pent up demand.
When deal chatter surfaces, a clear daily note can save time, so sign up for the free Market Briefs
Price tag, firepower, and the CEO's M&A playbook
Sanofi's finance chief, François-Xavier Roger, has signaled the company has room to do a sizable deal. Using a customary 30% markup to the pre-announcement share price, Insmed would run about €31 billion, or $34 billion - a level Jefferies analyst Michael Leuchten said is "not entirely out of reach." Some investors and analysts warned the likely price could stretch Sanofi, and Claus Henrik Johansen of Global Health Invest said whether Sanofi can convert the assets into sales and pipeline progress will decide if the deal is "strategically sound and value-enhancing for the shareholders of Sanofi." His caution: "It's not a cheap acquisition, and it leaves room for Sanofi to prove that it is the right owner of these assets."
If it closes, the deal would be the largest global biopharma transaction since late 2023, when Pfizer agreed to acquire Seagen Inc. for $43 billion.
Garijo has leaned on deals before. At Merck KGaA, she worked through a post pandemic slowdown and two major drug setbacks by striking acquisitions, including SpringWorks Therapeutics for $3.9 billion, while a pending $11.3 billion purchase of Bio-Techne followed two months after she left. When she arrived at Sanofi, the pipeline she took over had unnerved investors after multiple trial failures pushed Paul Hudson to depart, despite steady growth from Dupixent.
She has yet to show she can fix Sanofi's internal development challenges, and newly appointed R&D head Paulo Fontoura, formerly of Roche, has not had time to lay out potential changes. The bottom line: investors are getting a clearer look this week at her willingness to use M&A to jump start a turnaround.
What it means for your portfolio: a Sanofi-Insmed deal would swap significant revenue potential and development risk under Sanofi's umbrella and refocus growth on respiratory and rare-disease assets. Watch for any formal announcement, guidance on financing, and how Brinsupri, Arikayce, and late-stage respiratory programs would slot into Sanofi's growth plan.
When headlines shift quickly, get the five minute rundown that explains markets simply by subscribing to Market Briefs newsletter
